Market Overview

Oppenheimer Initiates Prothena With Outperform

UBS: Biotech Will Continue To Outperform In 2015
Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders

Analysts at Oppenheimer initiated coverage on shares of Prothena (NASDAQ: PRTA) with a Outperform rating.

The target price for Prothena is set to $40.

Prothena shares have dropped 1.50% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period.

Prothena's shares fell 0.71% to close at $20.94 yesterday.

Latest Ratings for PRTA

Jun 2015UBSInitiates Coverage onBuy
May 2015UBSInitiates Coverage onBuy
May 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for PRTA
View the Latest Analyst Ratings

Posted-In: OppenheimerInitiation Analyst Ratings


Related Articles (PRTA)

Get Benzinga's Newsletters